Figure S6 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance

Figure S6 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance

<p>Original picture</p>

Enregistré dans:

Détails bibliographiques
Auteur principal:	Xiaodong Shu (16721586) (author)
Autres auteurs:	Jianjie Li (16721589) (author), Un In Chan (16721592) (author), Sek Man Su (16721595) (author), Changxiang Shi (16721598) (author), Xin Zhang (16721601) (author), Tingting An (16721604) (author), Jun Xu (16721607) (author), Lihua Mo (16721610) (author), Jianlin Liu (16721613) (author), Yuqing Wang (16721616) (author), Xiaoling Li (16721619) (author), Min Deng (16721622) (author), Josh Haipeng Lei (16721625) (author), Chunfei Wang (16721628) (author), Hao Tian (16721631) (author), Sun Heng (16721634) (author), Joong Sup Shim (16721637) (author), Xuanjun Zhang (16721640) (author), Yunlu Dai (16721643) (author), Zhicheng Yao (16721646) (author), Xiaying Kuang (16721649) (author), Ying Lin (15293140) (author), Chu-Xia Deng (16721652) (author), Xiaoling Xu (16721655) (author)
Publié:	2025
Sujets:	Cancer Cancer Biology Tumor Biology Immuno-oncology Breast Cancer Immunology Immunotherapy Checkpoint blockade Oncogenes & Tumor Suppressors Progression, Invasion & Metastasis Tumor Microenvironment
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Figure S1 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
par: Xiaodong Shu (16721586)
Publié: (2025)

Figure S2 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
par: Xiaodong Shu (16721586)
Publié: (2025)

Figure S3 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
par: Xiaodong Shu (16721586)
Publié: (2025)

Figure S4 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
par: Xiaodong Shu (16721586)
Publié: (2025)

Figure S5 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
par: Xiaodong Shu (16721586)
Publié: (2025)

Figure S7 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
par: Xiaodong Shu (16721586)
Publié: (2025)

Table S1-S9 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
par: Xiaodong Shu (16721586)
Publié: (2025)

Supplementary Table S1 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
par: Christine Pich-Bavastro (16509238)
Publié: (2025)

Supplementary Table S2 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
par: Christine Pich-Bavastro (16509238)
Publié: (2025)

Supplementary Table S3 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
par: Christine Pich-Bavastro (16509238)
Publié: (2025)

Supplementary Table S4 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
par: Christine Pich-Bavastro (16509238)
Publié: (2025)

Supplementary Table S5 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
par: Christine Pich-Bavastro (16509238)
Publié: (2025)

Supplementary Table S6 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
par: Christine Pich-Bavastro (16509238)
Publié: (2025)

Supplementary Table S7 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
par: Christine Pich-Bavastro (16509238)
Publié: (2025)

Supplementary Data from Attenuation of Sialylation Augments Antitumor Immunity and Improves Response to Immunotherapy in Ovarian Cancer
par: Kankan Cao (16437263)
Publié: (2025)

Table S8 from Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes
par: Sung-Eun Lee (14855067)
Publié: (2025)

Supplementary Table S1 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
par: Aleksandar Obradovic (7549517)
Publié: (2025)

Supplementary Table S2 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
par: Aleksandar Obradovic (7549517)
Publié: (2025)

Table S1-S8 from Urinary Tumor DNA MRD Analysis to Identify Responders to Neoadjuvant Immunotherapy in Muscle-invasive Bladder Cancer
par: Ruiyun Zhang (17142498)
Publié: (2025)

Figure 1 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
par: Clare Vesely (505402)
Publié: (2025)

Figure 2 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
par: Clare Vesely (505402)
Publié: (2025)

Figure 3 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
par: Clare Vesely (505402)
Publié: (2025)

Figure 4 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
par: Clare Vesely (505402)
Publié: (2025)

Figure 5 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
par: Clare Vesely (505402)
Publié: (2025)

Table 1 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
par: Clare Vesely (505402)
Publié: (2025)

Supplementary Figures from NKG7 Is Required for Optimal Antitumor T-cell Immunity
par: Xian-Yang Li (15022958)
Publié: (2025)

Supplementary Data 1 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
par: Arianna Draghi (15126339)
Publié: (2025)

Supplementary Data 2 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
par: Arianna Draghi (15126339)
Publié: (2025)

Supplementary Data 3 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
par: Arianna Draghi (15126339)
Publié: (2025)

Supplementary Tables from MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages
par: Renumathy Dhanasekaran (14962092)
Publié: (2025)

Supplementary Figure S1 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
par: Sonia A. Patel (15055688)
Publié: (2025)

Supplementary Figure S2 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
par: Sonia A. Patel (15055688)
Publié: (2025)

Supplementary Figure S3 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
par: Sonia A. Patel (15055688)
Publié: (2025)

Supplementary Figure S4 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
par: Sonia A. Patel (15055688)
Publié: (2025)

Supplementary Figure S5 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
par: Sonia A. Patel (15055688)
Publié: (2025)

Supplementary video 1 from Depletion of Conventional Type-1 Dendritic Cells in Established Tumors Suppresses Immunotherapy Efficacy
par: Alvaro Teijeira (14962650)
Publié: (2025)

Supplementary video 2 from Depletion of Conventional Type-1 Dendritic Cells in Established Tumors Suppresses Immunotherapy Efficacy
par: Alvaro Teijeira (14962650)
Publié: (2025)

Supplementary video 3 from Depletion of Conventional Type-1 Dendritic Cells in Established Tumors Suppresses Immunotherapy Efficacy
par: Alvaro Teijeira (14962650)
Publié: (2025)

Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
par: Hansol Lee (15054787)
Publié: (2025)

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
par: Hansol Lee (15054787)
Publié: (2025)

Cannot write session to /tmp/vufind_sessions/sess_m5s2jfo1ha1f345fku3l2gmonv